BSX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BSX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.
Boston Scientific's current Total Payout Ratio is 0.00.
The historical data trend for Boston Scientific's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Payout Ratio | Get a 7-Day Free Trial | - | 5.02 | 0.05 | 0.08 | 0.02 |
Boston Scientific Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Total Payout Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Devices subindustry, Boston Scientific's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Total Payout Ratio falls into.
Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.
Boston Scientific's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Total Payout Ratio | = | - (Repurchase of Stock | + | Issuance of Stock | + | Cash Flow for Dividends) | / | Net Income |
= | - (0 | + | 0 | + | -28) | / | 1592 | |
= | 0.02 |
Boston Scientific's Total Payout Ratio for the quarter that ended in Sep. 2024 is calculated as
Total Payout Ratio | = | - (Repurchase of Stock | + | Issuance of Stock | + | Cash Flow for Dividends) | / | Net Income |
= | - (0 | + | 0 | + | 0) | / | 469 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Boston Scientific's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael F Mahoney | officer: President | BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Wendy Carruthers | officer: SVP, Human Resources | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Joseph Michael Fitzgerald | officer: SVP & President, Endovascular | C/O BOSTON SCIENTIFIC, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Arthur C Butcher | officer: SVP&Pres, Endoscopy | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752 |
Jeffrey B. Mirviss | officer: SVP&Pres, Periph Intervent | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Daniel J. Brennan | officer: EVP and CFO | BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Vance R Brown | officer: SVP, GC and Corp. Secretary | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752 |
Thepaut Eric Francis Yves | officer: SVP & Pres, Europe | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752 |
Charles J Dockendorff | director | COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048 |
John Bradley Sorenson | officer: SVP, Glob Ops & Qual | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752 |
Edward J Ludwig | director | C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417 |
Susan E Morano | director | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752 |
Jessica L Mega | director | 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037 |
Jonathan Monson | officer: VP, Corp Controller and CAO | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752 |
Nelda J Connors | director | BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
From GuruFocus
By GuruFocus Research • 04-03-2024
By PRNewswire • 08-13-2024
By GuruFocus Research • 03-20-2024
By PRNewswire • 05-18-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 04-25-2024
By PRNewswire • 02-27-2024
By PRNewswire • 05-08-2024
By GuruFocus Research • 02-27-2024
By PRNewswire • 06-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.